BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

890 related articles for article (PubMed ID: 8723881)

  • 1. Protection of BALB/c mice against homologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4.
    Winter AJ; Schurig GG; Boyle SM; Sriranganathan N; Bevins JS; Enright FM; Elzer PH; Kopec JD
    Am J Vet Res; 1996 May; 57(5):677-83. PubMed ID: 8723881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of recombinant Brucella abortus RB51 vaccines against B. melitensis infection in mice.
    Vemulapalli R; Contreras A; Sanakkayala N; Sriranganathan N; Boyle SM; Schurig GG
    Vet Microbiol; 2004 Sep; 102(3-4):237-45. PubMed ID: 15327798
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and evaluation as vaccines in mice of Brucella melitensis Rev.1 single and double deletion mutants of the bp26 and omp31 genes coding for antigens of diagnostic significance in ovine brucellosis.
    Cloeckaert A; Jacques I; Grilló MJ; Marín CM; Grayon M; Blasco JM; Verger JM
    Vaccine; 2004 Jul; 22(21-22):2827-35. PubMed ID: 15246618
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Brucella melitensis B115 as rough-phenotype vaccine against B. melitensis and B. ovis infections.
    Adone R; Francia M; Ciuchini F
    Vaccine; 2008 Sep; 26(38):4913-7. PubMed ID: 18675869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. B. melitensis rough strain B115 is protective against heterologous Brucella spp. infections.
    Adone R; Francia M; Pistoia C; Pesciaroli M; Pasquali P
    Vaccine; 2011 Mar; 29(14):2523-9. PubMed ID: 21300102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Over-expression of homologous antigens in a leucine auxotroph of Brucella abortus strain RB51 protects mice against a virulent B. suis challenge.
    Rajasekaran P; Surendran N; Seleem MN; Sriranganathan N; Schurig GG; Boyle SM
    Vaccine; 2011 Apr; 29(17):3106-10. PubMed ID: 21376799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A recombinant subunit vaccine based on the insertion of 27 amino acids from Omp31 to the N-terminus of BLS induced a similar degree of protection against B. ovis than Rev.1 vaccination.
    Cassataro J; Pasquevich KA; Estein SM; Laplagne DA; Velikovsky CA; de la Barrera S; Bowden R; Fossati CA; Giambartolomei GH; Goldbaum FA
    Vaccine; 2007 May; 25(22):4437-46. PubMed ID: 17442465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.
    Al-Mariri A; Tibor A; Mertens P; De Bolle X; Michel P; Godefroid J; Walravens K; Letesson JJ
    Infect Immun; 2001 Aug; 69(8):4816-22. PubMed ID: 11447155
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective role of antibodies induced by Brucella melitensis B115 against B. melitensis and Brucella abortus infections in mice.
    Adone R; Francia M; Pistoia C; Petrucci P; Pesciaroli M; Pasquali P
    Vaccine; 2012 Jun; 30(27):3992-5. PubMed ID: 22521283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venezuelan field trials of vaccines against brucellosis in swine.
    Lord VR; Cherwonogrodzky JW; Schurig GG; Lord RD; Marcano MJ; Meléndez GE
    Am J Vet Res; 1998 May; 59(5):546-51. PubMed ID: 9582954
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccination with Brucella abortus rough mutant RB51 protects BALB/c mice against virulent strains of Brucella abortus, Brucella melitensis, and Brucella ovis.
    Jiménez de Bagüés MP; Elzer PH; Jones SM; Blasco JM; Enright FM; Schurig GG; Winter AJ
    Infect Immun; 1994 Nov; 62(11):4990-6. PubMed ID: 7927779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral vaccination with Brucella melitensis WR201 protects mice against intranasal challenge with virulent Brucella melitensis 16M.
    Izadjoo MJ; Bhattacharjee AK; Paranavitana CM; Hadfield TL; Hoover DL
    Infect Immun; 2004 Jul; 72(7):4031-9. PubMed ID: 15213148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological responses and protective efficacy against Brucella melitensis induced by bp26 and omp31 B. melitensis Rev.1 deletion mutants in sheep.
    Jacques I; Verger JM; Laroucau K; Grayon M; Vizcaino N; Peix A; Cortade F; Carreras F; Guilloteau LA
    Vaccine; 2007 Jan; 25(5):794-805. PubMed ID: 17070627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increases of efficacy as vaccine against Brucella abortus infection in mice by simultaneous inoculation with avirulent smooth bvrS/bvrR and rough wbkA mutants.
    Grilló MJ; Manterola L; de Miguel MJ; Muñoz PM; Blasco JM; Moriyón I; López-Goñi I
    Vaccine; 2006 Apr; 24(15):2910-6. PubMed ID: 16439039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rough vaccines in animal brucellosis: structural and genetic basis and present status.
    Moriyón I; Grilló MJ; Monreal D; González D; Marín C; López-Goñi I; Mainar-Jaime RC; Moreno E; Blasco JM
    Vet Res; 2004; 35(1):1-38. PubMed ID: 15099501
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunization with recombinant Brucella species outer membrane protein Omp16 or Omp19 in adjuvant induces specific CD4+ and CD8+ T cells as well as systemic and oral protection against Brucella abortus infection.
    Pasquevich KA; Estein SM; García Samartino C; Zwerdling A; Coria LM; Barrionuevo P; Fossati CA; Giambartolomei GH; Cassataro J
    Infect Immun; 2009 Jan; 77(1):436-45. PubMed ID: 18981242
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rough mutants defective in core and O-polysaccharide synthesis and export induce antibodies reacting in an indirect ELISA with smooth lipopolysaccharide and are less effective than Rev 1 vaccine against Brucella melitensis infection of sheep.
    Barrio MB; Grilló MJ; Muñoz PM; Jacques I; González D; de Miguel MJ; Marín CM; Barberán M; Letesson JJ; Gorvel JP; Moriyón I; Blasco JM; Zygmunt MS
    Vaccine; 2009 Mar; 27(11):1741-9. PubMed ID: 19186196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the immunogenicity and the protective efficacy in mice of a DNA vaccine encoding SP41 from Brucella melitensis.
    Al-Mariri A; Abbady AQ
    J Infect Dev Ctries; 2013 Apr; 7(4):329-37. PubMed ID: 23592643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A repA-based ELISA for discriminating cattle vaccinated with Brucella suis 2 from those naturally infected with Brucella abortus and Brucella melitensis.
    Wang JY; Wu N; Liu WH; Ren JJ; Tang P; Qiu YH; Wang CY; Chang CD; Liu HJ
    Mol Cell Probes; 2014; 28(5-6):251-4. PubMed ID: 24941369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of vaccination strategies against intranasal challenge with Brucella abortus in BALB/c mice.
    Surendran N; Sriranganathan N; Lawler H; Boyle SM; Hiltbold EM; Heid B; Zimmerman K; Witonsky SG
    Vaccine; 2011 Mar; 29(15):2749-55. PubMed ID: 21316499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.